2-Arylpropionic Acid Pyrazolamides as Cannabinoid CB2 Receptor Inverse Agonists Endowed with Anti-Inflammatory Properties
Open Access
- 6 December 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (12) , 1519
Abstract
Among the most recent proposals regarding the mechanism of action of dipyrone, the modulation of cannabinoid receptors CB1 and CB2 appears to be a promising hypothesis. In this context, the present work describes a series of five novel pyrazolamides (7–11) designed as molecular hybrids of dipyrone metabolites and NSAIDs, such as ibuprofen and flurbiprofen. Target compounds were obtained in good overall yields (50–80%) by classical amide coupling between 4-aminoantipyrine and arylacetic or arylpropionic acids, followed in some cases by N-methylation of the amide group. The compounds presented good physicochemical properties in addition to stability to chemical (pH 2 and 7.4) and enzymatic (plasma esterases) hydrolysis and showed medium to high gastrointestinal and BBB permeabilities in the PAMPA assay. When subjected to functional testing on CB1- or CB2-transfected cells, compounds demonstrated an inverse agonist profile on CB2 receptors and the further characterization of compound LASSBio-2265 (11) revealed moderate binding affinity to CB2 receptor (Ki = 16 µM) with an EC50 = 0.36 µM (Emax = 63%). LASSBio-2265 (11) (at 1, 3, and 10 mg/kg p.o.) was investigated in the formalin test in mice and a remarkable analgesic activity in the late inflammatory phase was observed, suggesting it could be promising for the treatment of pain syndromes associated with chronic inflammatory diseases.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES) (Finance Code 001)
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (465.249/2014-0)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/010.001273/2016, E-26/202.878/2018, SEI-260003/003613/2022, E-26/202.763/2018, SEI-260003/001182/2020)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (304394/2017-3)
This publication has 58 references indexed in Scilit:
- Novel bioactive metabolites of dipyrone (metamizol)Bioorganic & Medicinal Chemistry, 2012
- Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociceptionPharmacology Biochemistry and Behavior, 2011
- The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effectsNeuropharmacology, 2011
- Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the BedsideNeurotherapeutics, 2009
- Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory PainChemistry & Biology, 2009
- In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitorsInternational Journal of Pharmaceutics, 2008
- Cannabinoid CB2receptors: a therapeutic target for the treatment of inflammatory and neuropathic painBritish Journal of Pharmacology, 2008
- Biology and therapeutic potential of cannabinoid CB2receptor inverse agonistsBritish Journal of Pharmacology, 2008
- The inhibition of monoacylglycerol lipase by URB602 showed an anti‐inflammatory and anti‐nociceptive effect in a murine model of acute inflammationBritish Journal of Pharmacology, 2007
- The antinociceptive effects of intraplantar injections of 2‐arachidonoyl glycerol are mediated by cannabinoid CB2receptorsBritish Journal of Pharmacology, 2007